Based on the anti-angiogenic activity of DX-2400, this study also evaluated the combination of DX-2400 and bevacizumab (an antibody against VEGF) and found that it retarded tumor growth to a greater extent than treatment with either agent individually in the MDA-MB-231 xenograft model, suggesting a promising approach of anti-angiogenic agents in combination with MMP-14 inhibitor for synergistic anti-tumor effects in breast cancer. This evidence concerns the gene MMP14 and breast carcinoma.